Healthcare
OKYO Pharma Limited(OKYO)
Live Price
Offline$1.59
+1.27% today
1Y Change
-36.44%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $60.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -19900.0%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
OKYO Pharma Limited (OKYO) is a Healthcare stock with a market cap of $60.00M and listed on NASDAQ. The stock last traded around $1.59 and down 36.4% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -19900.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -19900.0%, free cash flow +80.9% with operating margin 0.0% and ROIC 154.2%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines OKYO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q2 2026 was reported on Apr 29, 2026 with an EPS surprise of +11.1%.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -19900.0%, with operating margin around 0.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 9, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 Apr 29, 2026 | +11.1% | +2.6% | +10.5% | +12.5% |
Q1 2026 Jan 23, 2026 | +16.1% | -2.7% | -7.7% | -23.4% |
Q4 2025 Oct 20, 2025 | -50.0% | -4.5% | +9.1% | -11.7% |
Benchmark Edge
OKYO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
OKYO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
OKYO Max Drawdown
-54.43%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for OKYO and SPY.
Company Overview
OKYO Pharma Limited
NASDAQ Capital Market
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
- Leadership
- Robert J. Dempsey
- IPO Date
- May 17, 2022
- Employees
- 3
- Street Address
- 55 Park Lane
- Mailing
- London, W1K 1NA
- Region
- London, GB
- Reporting Currency
- USD
- Investor Line
- 44 20 7495 2379
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -19900.0%
- Free Cash Flow
- +80.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 102.9%
- ROIC
- 154.2%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.58
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.